Wyeth stumbles badly trying to develop new drugs

The analysts have been picking over Wyeth's carcass over the past few days as they assess a string of woeful developments that have left the company stripped of three of its leading drug candidates. With its hep C trial suspended at the end of last week, the analysts are raising questions about the company's ability to design trials properly. And a pair of FDA rejections hasn't helped the company's reputation one little bit. Add it all up and you see a big pharma company having a terrible time coming up with new winners to replace its fading stockpile of approved drugs. The next big milestone for Wyeth: New mid-stage data from a study for a new Alzheimer's drug being developed with Elan.

- read the report from Forbes

Related Articles:
Wyeth stock down after several setbacks. Report
ViroPharma, Wyeth halt HCV study. Report
Wyeth, Solvay handed FDA rejection. Report
Solvay expands development pact with Wyeth. Report
FDA demands more data on Wyeth's Pristiq. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.